An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.

In working through the Winter case files, I often felt pinpricks of déjà vu: an exact turn of phrase, an absurdly specific ...

Compassionate-use lurbinectedin demonstrates modest yet consistent efficacy and is well tolerated in patients with ...

With EAGLE, lung cancer biopsy analysis is expedited, accurately predicting EGFR mutations and streamlining the diagnostic process for better patient outcomes.

(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today ...

The global oncology drug market is currently valued at over 200 billion dollars and is expected to more than double to 532 billion dollars by 2031. T ...

Pleurisy Market Pleurisy Market is valued at USD 1.83 billion In 2024 and is expected to grow at the rate of CAGR of 6.94%, is expected to reach USD 3.23 billion by 2032 Innovating pleurisy care ...

"The brain has no pain receptors. Although it processes pain signals from other parts of the body, the brain itself cannot ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Smart home healthcare market will evolve toward embedded edge intelligence, energy-aware sensors, and interoperable standards ...